Faruqi & Faruqi, LLP. Launches Investigation Against AngioDynamics Inc. (ANGO) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors In The Manner It Seeks Executive Compensation Approval
Faruqi & Faruqi, LLP, a leading national securities firm headquartered
in New York City, is investigating the Board of Directors of
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of AngioDynamics Inc. (“AngioDynamics” or the “Company”) (NASDAQ: ANGO) for potential breaches of fiduciary duties in connection with their conduct of seeking shareholders’ approval of the compensation for the Company’s named executive officers. The terms of the compensation to be awarded to the Company’s executive officers are outlined in the Proxy Statement on Form Schedule 14A that the Company filed with the Securities and Exchange Commission on September 10, 2012. Request more information now by clicking here: www.faruqilaw.com/ANGO.There is no cost or obligation to you. Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients. If you own common stock in AngioDynamics and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/ANGO or contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330. Attorney Advertising. (C) 2012 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.